Advertisement

Overview of Cancer and Thrombosis

  • Axel C. Matzdorff
  • David Green
Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 148)

Historically, the French physician and scientist Armand Trousseau (1801–1867) has been honored as the first scientist to report the association between malignant disorders and thromboembolism [1]. In 1861, in his book Clinique medicale de l'Hôtel-Dieu de Paris, he postulated that most patients with cachexia and thrombosis have undiagnosed cancer. A few years after his observation Trousseau noted thrombophlebitis of his left upper arm and a few months later he succumbed to gastric cancer.

Keywords

Venous Thromboembolism Polycythemia Vera Essential Thrombocythemia Gemtuzumab Ozogamicin Malignant Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Khorana A. Malignancy, thrombosis, and Trousseau: the case for an eponym. J Thromb Haemost 2003;1:2463–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Virchow R. Thrombosis and emboli. Translated by AC Matzdorff and WR Bell. Science History Publications, Canton, MS, 1998Google Scholar
  3. 3.
    Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575–9.PubMedGoogle Scholar
  4. 4.
    Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood 1983;62:14–31.PubMedGoogle Scholar
  5. 5.
    Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007;98:656–61.PubMedGoogle Scholar
  6. 6.
    Goldschmidt N, Linetsky E, Shalom E, et al. High incidence of thromboembolism in patients with central nervous system lymphoma. Cancer 2003;98:1239–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Schulman S, Lindmarker P, for the duration of anticoagulation (DURAC) trial. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N Engl J Med 2000;342:1953–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Di Nisio M, Otten HM, Piccioli A, et al. Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost 2005;3:2391–6.CrossRefGoogle Scholar
  9. 9.
    Carrier M, Wells PS, Tao H, Rodger MA. Screening for occult malignancy in patients with idiopathic venous thromboembolism (VTE) evaluation (SOME TRIAL): a prospective pilot cohort study using comprehensive abdomen/pelvis computed tomography (CCT). J Thromb Haemost 2007;5(Supplement 2):P-S-556.Google Scholar
  10. 10.
    Südhoff T, Schneider W. Fibrinolytic mechanisms in tumor growth and spreading. Clin Investig 1992;70:631–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Edwards RL, Silver J, Rickles FR. Human tumor procoagulants: registry of the subcommittee on haemostasis and malignancy of the scientific and standardization committee, International Society on Thrombosis and Haemostasis. Thromb Haemost 1993;69:205–13.PubMedGoogle Scholar
  12. 12.
    Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999;340:994–1004PubMedCrossRefGoogle Scholar
  13. 13.
    Palumbo JS, Talmage KE, Massari JV, et al. Tumor cell–associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell–dependent and –independent mechanisms. Blood 2007;110:133–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Gao D, Nolan DJ, Mellick AS, et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008;319:195–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim YJ, Borsig L, Han HL, et al. Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium. Am J Pathol 1999;155:461–72.PubMedCrossRefGoogle Scholar
  16. 16.
    Look M, van Putten W, Duffy M, et al. Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost 2003;91:538–48.Google Scholar
  17. 17.
    Chappuis PI, Dieterich B, Sciretta V, et al. Functional evaluation of plasmin formation in primary breast cancer. J Clin Oncol 2001;19:2731–2738PubMedGoogle Scholar
  18. 18.
    Aulmann C, Seufert P, Sandherr M, et al. A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis. Internist 2007;48:1015–9PubMedCrossRefGoogle Scholar
  19. 19.
    Cooper DL, Sandler AB, Wilson LD, Duffy TP. Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocaproic acid. Cancer 1992;70:656–8PubMedCrossRefGoogle Scholar
  20. 20.
    Caine GJ, Stonelake PS, Rea D, Lip GYH. Coagulopathic complications in breast cancer. Cancer 2003;998:1578–86.CrossRefGoogle Scholar
  21. 21.
    Santos AB, Llamas P, Román A, et al. Evaluation of thrombophilic states in myeloma patients receiving thalidomide: a reasonable doubt. Br J Haematol 2003;122:159–67.PubMedCrossRefGoogle Scholar
  22. 22.
    Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490–505.PubMedCrossRefGoogle Scholar
  23. 23.
    Palumbo A, Cavo M, Bringhen S, et al. A prospective, randomized, phase III study of enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens. Blood 2007;110 (Suppl. 1, Part 1):98a.Google Scholar
  24. 24.
    Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis N Engl J Med 2003;49:1227–35Google Scholar
  25. 25.
    Cronin CG, Lohan DG, Keane M. Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. Am J Roentgenol 2007;189:162–70.CrossRefGoogle Scholar
  26. 26.
    Carrier M, Lee A, Bates SM, et al. Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis (DVT) in cancer patients. J Thromb Haemost 2007;5(Suppl. 2): P-S-555.Google Scholar
  27. 27.
    Nowak-Göttl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999;93:1595–9.PubMedGoogle Scholar
  28. 28.
    Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008;6:70–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Dicato MA, Schroell-Metzger B, Bosseler M, et al. The mutations V Leiden, MTHFR and PT do not need to be determined in cancer patients with venous thromboembolic disorders unless they have a personal or family history of thrombophilia. Blood 2003;102 (Suppl.1, Part 2):118b.Google Scholar
  30. 30.
    Fijnheer R, Paijmans B, Verdonck LF, et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002;118:267–70.PubMedCrossRefGoogle Scholar
  31. 31.
    Mandala M, Curigliano G, Bucciarelli P, et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol 2004;15:590–3.PubMedCrossRefGoogle Scholar
  32. 32.
    Ferretti G, Bria E, Felici A, et al. Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden? Ann Oncol 2006;17:528–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Kakkar AK, Williamson RCN. Prevention of VTE in cancer patients. Semin Thromb Hemost 1999;25:239–243.PubMedCrossRefGoogle Scholar
  34. 34.
    ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84:1099–103.CrossRefGoogle Scholar
  35. 35.
    Bergqvist D, Agnelli G, Cohen AT, et al. for the ENOXACAN II investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975–80.PubMedCrossRefGoogle Scholar
  36. 36.
    Geerts WH, Pineo PF, Heit JA. Prevention of thromboembolism. Chest 2004;126:338S–400S.PubMedCrossRefGoogle Scholar
  37. 37.
    Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339–46.PubMedCrossRefGoogle Scholar
  38. 38.
    van Rooden CJ, Tesselaar MET, Osanto S, et al. Deep vein thrombosis associated with central venous catheters – a review. J Thromb Haemost 2005;3:2409–19.PubMedCrossRefGoogle Scholar
  39. 39.
    Bern MM, Lokich JJ,Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990;112:423–8.PubMedGoogle Scholar
  40. 40.
    Monreal M, Alastrue A, Rull M,et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices – prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996;75:251–3.PubMedGoogle Scholar
  41. 41.
    Huisman MV. Is antithrombotic prophylaxis required in cancer patients with central venous catheters? Yes for special patient groups. J Thromb Haemost 2006;4:10–3.PubMedCrossRefGoogle Scholar
  42. 42.
    Kovacs MJ, Kahn SR, Rodger M, et al. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007;5:1650–3.PubMedCrossRefGoogle Scholar
  43. 43.
    Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484–88.PubMedCrossRefGoogle Scholar
  44. 44.
    Lee AYY, Levine MN, Baker RI, et al. For the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146–53.PubMedCrossRefGoogle Scholar
  45. 45.
    Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002;162:1729–35.PubMedCrossRefGoogle Scholar
  46. 46.
    Hull RD, Pineo GF, Brant RF, et al. For the LITE-Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062–72.PubMedCrossRefGoogle Scholar
  47. 47.
    Wittkowsky AK. Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost 2006;4:2090–1.PubMedCrossRefGoogle Scholar
  48. 48.
    Gerber DE, Grossman SA, Streiff MB, et al. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006;24:1310–8.PubMedCrossRefGoogle Scholar
  49. 49.
    El-Shami K, Griffiths E, Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. Oncologist 2007;12:518–23.PubMedCrossRefGoogle Scholar
  50. 50.
    Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337–43.PubMedCrossRefGoogle Scholar
  51. 51.
    Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617 V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007;110:840–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310–3.PubMedCrossRefGoogle Scholar
  53. 53.
    Landolfi R, Marchioli R, Kutti J, et al. For the European Collaboration on Low-dose Aspirin in Polycythemia Vera Investigators (ECLAP): Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114–24.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Hematology/OncologyCaritasklinikGermany
  2. 2.Chicago

Personalised recommendations